Explore lipid formulations with reported pancreatic RNA expression. Study summaries distinguish pancreas-level signals from delivery to defined pancreatic cells.
6 products currently listedResearch-use products only
Evidence noteCategory membership indicates research relevance. Organ targeting, cell specificity and performance must be verified from the formulation and study conditions cited for each product.
Intraperitoneal 200Oi10 LNPs produced pancreatic luciferase expression after intraperitoneal administration in mice. Helper-lipid changes further altered the organ-expression profile; this does not establish route-independent pancreatic tropism.
[1] Source Main Figs. 1–2; administration-route and helper-lipid comparison
Intraperitoneal 514O6,10 LNPs produced pancreatic luciferase expression after intraperitoneal administration in mice. Helper-lipid changes further altered the organ-expression profile; this does not establish route-independent pancreatic tropism.
[1] Source Main Figs. 1–2; administration-route and helper-lipid comparison
Intraperitoneal 306Oi10 LNPs produced pancreatic luciferase expression after intraperitoneal administration in mice. Helper-lipid changes further altered the organ-expression profile; this does not establish route-independent pancreatic tropism.
[1] Source Main Figs. 1–2; administration-route and helper-lipid comparison
Intraperitoneal GL5 in both GL5-3 and GL5-4 LNP formulations produced pancreatic luciferase expression after intraperitoneal administration in mice; expression was also observed in the stomach.
[2] Source Main Fig. 5G–J; intraperitoneal organ-expression results
Intraperitoneal AA76-containing AH-LNPs supported functional mRNA expression and gene-modulation studies in the pancreas after intraperitoneal administration. Pancreatic delivery belongs to the complete protein-interacting formulation and the tested route.
[3] Source Primary Results; pancreatic reporter and therapeutic-mRNA expression experiments
Intraperitoneal 4A2-B8-PH LNPs supported mRNA expression in pancreatic ductal epithelial cells after intraperitoneal administration in mice. IL-12-mRNA efficacy was assessed in a separate orthotopic pancreatic-cancer experiment.
[4] Source Primary abstract; ductal-cell expression and IL-12-mRNA experiments
Each entry identifies the reported lipid or complete formulation, experimental setting and source. Reference products and limited-expression findings are labeled in their study context.
200Oi10 is a highly potent, biodegradable ionizable lipidoid optimized for targeted mRNA delivery, with its organ tropism dynamic to the route of administration. Under intravenous injection, it demonstrates an extraordinary 97.7% liver specificity mediated by endogenous ApoE binding. Strikingly, shifting to intraperitoneal injection redirects its tropism, yielding up to 46.4% pancreatic targeting, which can be further boosted when co-formulated with DOTAP. Featuring ester-conjugated cleavable tails, 200Oi10 guarantees rapid metabolic clearance and negligible tissue accumulation toxicity, making it an exceptional candidate for localized pancreatic therapy and efficient hepatic gene delivery.
AA76-lipid is a dipeptide-modified ionizable lipid, engineered with an arginine-histidine motif, that constitutes the core of the pancreatic-targeted AH-LNP delivery platform. Its chemical architecture, characterized by an externally positioned and C-terminally modified arginine residue, was identified through systematic screening as the optimal structure for function. Upon intraperitoneal administration, AH-LNPs formulated with this lipid interact with proteins in the peritoneal fluid, undergoing dynamic assembly into significantly larger complexes. This substantial increase in size (from ~100 nm to over 360 nm) exploits a physical targeting principle termed the Capsule-filter-mediated pancreatic targeting (CAMP) mechanism. Large particles are selectively filtered out by the dense capsules of other abdominal organs, leading to preferential enrichment in the capsule-deficient pancreas. Concurrently, the arginine-histidine motif directs the formation of a distinct protein corona enriched with apolipoproteins (e.g., APOE, APOB-100), which mimics very-low-density lipoprotein (VLDL). This corona enables efficient cellular internalization primarily into pancreatic stromal cells via VLDL receptor (VLDLR)-mediated endocytosis, known as the VMP pathway. The synergistic integration of the physical CAMP targeting and the biological VMP uptake mechanisms empowers AA76-lipid-based AH-LNPs to achieve highly specific, potent, and sustained mRNA delivery and gene editing within the pancreas across multiple species, demonstrating exceptional therapeutic efficacy in models of both autoimmune pancreatitis and pancreatic cancer.
306Oi10 is a branched ionizable lipid that can be used to construct lipid nanoparticles (LNPs) for delivering messenger RNA. The surface ionization of lipid nanoparticles is related to the effectiveness of mRNA delivery. The tail of 306Oi10 has a one-carbon branch, which provides it with stronger surface ionization compared to lipids with linear tails, thereby enhancing its mRNA delivery efficacy. 306Oi10 can be used in research related to mRNA delivery.
4A2-B8-PH is an optimally designed thioketal-incorporated biodegradable ionizable lipid (TBIL) for mRNA delivery to pancreatic ductal epithelial cells. It features a 4A2 headgroup with three tertiary amines, a biodegradable thioketal-based B8 linker, and a branched PH tail. The thioketal linker enables ROS-responsive degradation in the tumor microenvironment, enhancing endosomal escape and mRNA release. In vivo, 4A2-B8-PH LNPs achieve 98.3% pancreas-specific targeting after intraperitoneal administration, with a 218-fold improvement in delivery efficiency compared to previous benchmarks. It successfully transfects 30.5% of pancreatic ductal epithelial cells and induces complete tumor regression in orthotopic PDAC models via IL-12 mRNA therapy, demonstrating high efficacy and safety.
GL5 is an ionizable guanidine-based lipid nanoparticle (G-LNP) designed for superior mRNA delivery. Its guanidinocarbonyl-pyrrole (GCP) headgroup enables pH-responsive behavior and strong mRNA binding via bidentate hydrogen bonds. The cholesterol-free GL5-3 formulation forms compact, stable nanoparticles (~90-120 nm) that exhibit excellent spleen-targeting capability after intravenous injection.GL5-LNPs efficiently deliver mRNA to antigen-presenting cells (APCs), enhancing antigen presentation and T cell activation. In cancer immunotherapy models, GL5-based mRNA vaccines provided complete tumor protection and induced durable immune memory. The platform also enables mRNA delivery to other organs like the pancreas via different administration routes, demonstrating remarkable versatility and therapeutic potential.
